Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 10/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14382398 | 0.82 | IDH1 (0.43) | IDH1ARKDM4ESMN1; SMN2TSHR | |
| SCHEMBL18053161 | 0.78 | IDH1 (0.48) | IDH1KDM4EALDH1A1GAAIDO1 | |
| SCHEMBL559359 | 0.74 | NOS3 (0.52) | ARKDM4EALDH1A1GAATSHR | |
| SCHEMBL5127366 | 0.73 | IDH1 (0.43) | IDH1ARKDM4ESMN1; SMN2NPSR1 | |
| SCHEMBL21598412 | 0.73 | MAPK8 (0.36) | ARKDM4EBRD4ALDH1A1MAPT | |
| SCHEMBL31253097 | 0.73 | HRH4 (0.45) | ARKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16421171 | 0.73 | NOS3 (0.50) | KDM4EBRD4ALDH1A1MAPTGAA | |
| SCHEMBL1641172 | 0.73 | HRH4 (0.45) | ARKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL18369815 | 0.72 | ALDH1A1 (0.46) | IDH1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL21928096 | 0.71 | EGLN2 (0.40) | ARKDM4EALDH1A1SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417121-A1 | 4, 5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | Pfizer Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2012-02-09 | — | — | US | disclosed |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. | 2012-01-26 | — | — | US | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-2089367-B1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | PFIZER INC | 2010-11-04 | — | — | US | disclosed |
| WO-2010116282-A1 | 4, 5-DIHYDRO-LH-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | PFIZER INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-7781428-B2 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035131-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | IDH1 549/4885AR 1631/4885KDM4E 2571/4885 |
| US-20100280016-A1 | PYRAZOLINE COMPOUNDS | F12, CYP3A7, ABCG2 | IDH1 549/4885AR 1631/4885KDM4E 2571/4885 |
| US-20120022058-A1 | 4,5-DIHYDRO-1H-PYRAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NR3C2, REN, AGTR1 | IDH1 1533/4885AR 64/4885KDM4E 3652/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | IDH1 1621/4885AR 2350/4885KDM4E 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.